论文部分内容阅读
目的:通过研究HBV抗原定量对干扰素联合阿德福韦酯治疗慢性乙肝患者的临床疗效,探究HBsAg下降水平对治疗效果的预测作用。方法:选取于2013年1月-2014年1月在我院感染科就诊的HBeAg阳性慢性乙肝患者共36例。在治疗过程中对患者进行分组并研究其疗效。结果:对比患者在治疗24周和48周后的HBsAg水平,将患者依据疗效分组,B组患者两项指标下降幅度明显优于A组,两组指标对比差异有统计学意义(P<0.05)。结论:对慢性乙肝患者行干扰素联合阿德福韦酯治疗,HBsAg的下降对其有预测作用,可通过该方法筛选病毒抑制的患者,及时为针对性治疗提供参考。
OBJECTIVE: To investigate the clinical efficacy of HBV antigens in the treatment of chronic hepatitis B patients treated with interferon plus adefovir dipivoxil, and to investigate the predictive value of the reduction of HBsAg on the therapeutic effect. Methods: A total of 36 patients with HBeAg-positive chronic hepatitis B who were treated in our department’s infection department from January 2013 to January 2014 were selected. Patients were grouped and their efficacy assessed during treatment. Results: Comparing the HBsAg level of patients after 24 and 48 weeks of treatment, the two groups of patients were significantly better than group A according to the curative effect and group B. The difference between the two groups was statistically significant (P <0.05) . Conclusion: The treatment of chronic hepatitis B patients with interferon combined with adefovir dipivoxil, HBsAg decreased its predictive role, this method can be used to screen for patients with viral suppression, timely and targeted treatment for reference.